- Details
- Oliver Sartor discusses with Ravi Madan the implications of using PSMA PET scans in metastatic castration-resistant prostate cancer. Dr. Madan highlights concerns about prematurely changing treatments based on PSMA PET findings without established criteria for progression. He emphasizes the distinction between radiological progression and treatment failure, noting the lack of validated parameters...
|
- Details
- Zach Klaassen interviews Constantinos Zamboglou about a study on PSMA-PET/CT-guided salvage radiotherapy for recurrent prostate cancer after surgery. Dr. Zamboglou presents findings from a comparative analysis of PSMA-PET-guided and non-PSMA-guided salvage radiotherapy, using data from the SAKK09/10 trial and a retrospective database. The study demonstrates improved short- and mid-term biochemical...
|
- Details
- Oliver Sartor speaks with Alan Taylor about advances in radiopharmaceuticals for cancer treatment. Dr. Taylor discusses Clarity's focus on copper isotopes, particularly Copper-67 (Cu-67 or 67 Cu), for targeted therapy. He explains the company's innovative bisPSMA technology, which offers improved tumor uptake and retention compared to conventional PSMA agents. Dr. Taylor highlights Clarity's work...
|
- Details
- Oliver Sartor speaks with Michael Schultz about advances in radiopharmaceuticals for cancer treatment. Dr. Schultz discusses the advantages of using alpha-particle emitters, particularly lead-212, for targeted cancer therapy. He explains the rationale behind choosing lead-212, including its short half-life and the ability to use lead-203 for imaging. Dr. Schultz addresses distribution challenges a...
|
- Details
- Oliver Sartor speaks with Philip Kantoff about the future of radiopharmaceuticals in cancer treatment. Dr. Kantoff discusses the rationale behind using antibody-based approaches for PSMA-targeted therapies, particularly with actinium-225, citing better cancer cell retention and reduced toxicity to salivary and lacrimal glands compared to small molecules. He highlights promising early results from...
|
- Details
- Oliver Sartor speaks with Emanuele Ostuni about ARTBIO’s focus on radiopharmaceuticals, particularly lead-212. Dr. Ostuni explains ARTBIO’s choice of lead-212 for its short half-life, which better matches the biological half-lives of targeting ligands. He discusses the manufacturing and distribution challenges associated with short-lived isotopes and outlines ARTBIO’s approach to developing a netw...
|
- Details
- Andrea Miyahira discusses with Irene Casanova-Salas and Joaquin Mateo a Cancer Cell publication on using circulating tumor extracellular vesicles (EVs) to monitor metastatic prostate cancer evolution. The researchers describe their novel method for analyzing both DNA and RNA from EVs in patient plasma samples. They highlight the advantages of EV analysis over traditional ctDNA, including the abili...
|
- Details
- Rashid Sayyid and Zach Klaassen review the NCCN prostate cancer guideline updates regarding the prevention of symptomatic skeletal-related events in bone metastatic CRPC patients. They discuss the efficacy and safety profiles of denosumab and zoledronic acid, highlighting key clinical trials that have shaped current recommendations. The speakers emphasize the importance of considering dosing frequ...
|
- Details
- Andrea Miyahira interviews Michael Haffner about his group's study on the expression of TROP2, CEACAM5, and DLL3 in metastatic prostate cancer, published in NEJM Evidence. Dr. Haffner discusses their analysis of over 750 samples from 52 patients in a rapid autopsy cohort, examining protein expression across different molecular subtypes of castration-resistant prostate cancer. The study reveals dis...
|
- Details
- Alicia Morgans interviews Karim Fizazi about the updated survival and quality of life data from the PSMAfore trial. The study compares lutetium PSMA to second-line AR pathway inhibitors in metastatic castration-resistant prostate cancer patients who have progressed after one AR pathway inhibitor. Dr. Fizazi discusses the trial's findings, highlighting a significant improvement in radiographic prog...
|
